CINECA IRIS Institutional Research Information System

RADIN, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.059
EU - Europa 3.802
AS - Asia 2.654
SA - Sud America 604
AF - Africa 89
OC - Oceania 73
Continente sconosciuto - Info sul continente non disponibili 12
Totale 13.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.682
CN - Cina 1.317
IT - Italia 1.122
ES - Italia 532
JP - Giappone 396
IE - Irlanda 320
DE - Germania 282
FR - Francia 269
GB - Regno Unito 236
MX - Messico 195
BR - Brasile 179
SE - Svezia 163
KR - Corea 159
IN - India 149
CA - Canada 147
CO - Colombia 146
AR - Argentina 137
VN - Vietnam 128
NL - Olanda 111
PL - Polonia 88
UA - Ucraina 88
PT - Portogallo 77
TW - Taiwan 77
RU - Federazione Russa 76
AU - Australia 69
TR - Turchia 69
FI - Finlandia 61
HK - Hong Kong 56
GR - Grecia 51
RO - Romania 51
CL - Cile 46
AT - Austria 45
BE - Belgio 45
PE - Perù 44
IR - Iran 41
SA - Arabia Saudita 41
SG - Singapore 39
CH - Svizzera 38
IL - Israele 37
DK - Danimarca 36
EC - Ecuador 29
ID - Indonesia 28
EG - Egitto 24
PH - Filippine 21
TH - Thailandia 21
TN - Tunisia 18
DZ - Algeria 17
MA - Marocco 15
RS - Serbia 15
BG - Bulgaria 13
HU - Ungheria 13
PK - Pakistan 13
SI - Slovenia 13
CZ - Repubblica Ceca 12
MY - Malesia 11
NO - Norvegia 11
VE - Venezuela 11
CR - Costa Rica 10
EU - Europa 10
UZ - Uzbekistan 9
BO - Bolivia 7
GT - Guatemala 7
IQ - Iraq 7
EE - Estonia 6
HR - Croazia 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
DO - Repubblica Dominicana 4
LB - Libano 4
NZ - Nuova Zelanda 4
QA - Qatar 4
UY - Uruguay 4
BY - Bielorussia 3
JO - Giordania 3
KW - Kuwait 3
LI - Liechtenstein 3
SV - El Salvador 3
AM - Armenia 2
BD - Bangladesh 2
CU - Cuba 2
CY - Cipro 2
JE - Jersey 2
LK - Sri Lanka 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SC - Seychelles 2
TJ - Tagikistan 2
A1 - Anonimo 1
AL - Albania 1
AN - Antille olandesi 1
AP - ???statistics.table.value.countryCode.AP??? 1
BN - Brunei Darussalam 1
CM - Camerun 1
Totale 13.281
Salva come PNG Salva come JPEG
Città #
Redwood City 517
Chandler 503
Ann Arbor 429
Fairfield 416
Beijing 321
Dublin 309
Ashburn 268
Torino 245
Woodbridge 219
Wilmington 205
Houston 193
Seattle 166
Turin 147
Cambridge 129
Shanghai 126
Tokyo 92
Medford 91
Nyköping 91
Dearborn 86
Lubbock 83
New York 82
Princeton 80
Madrid 78
Pisa 76
Dong Ket 72
Guangzhou 64
Hangzhou 59
Nanjing 57
Jacksonville 56
Milan 55
Rome 52
San Diego 48
Buenos Aires 44
Barcelona 43
Bogotá 42
Boston 42
Mexico City 42
Taipei 42
Villeurbanne 42
Warsaw 41
Helsinki 39
Paris 39
Zhengzhou 38
Lima 37
Santiago 36
Chengdu 34
Hebei 33
Medellín 33
São Paulo 33
Berlin 30
Jinan 26
Los Angeles 26
Seoul 26
Singapore 26
Loma Linda 25
London 25
Mexico 25
Changsha 24
Chicago 24
Duncan 24
Mumbai 24
Munro 24
Toronto 24
Wuhan 24
Fuzhou 23
Hanoi 23
Athens 22
Brussels 21
Hyderabad 21
Ottawa 21
Riyadh 21
Santander 21
Chongqing 20
Lisbon 20
Shenyang 19
Vienna 19
Córdoba 18
Hong Kong 18
Quito 18
Birmingham 17
Tianjin 17
Central District 16
Cuauhtémoc 15
Falls Church 15
Guadalajara 15
Hefei 15
Kansas City 15
Norwalk 15
Amsterdam 14
Padova 14
San Francisco 14
Silver Spring 14
Valencia 14
Ankara 13
Atlanta 13
Delhi 13
Guiyang 13
Moscow 13
Polska 13
Sevilla 13
Totale 7.058
Salva come PNG Salva come JPEG
Nome #
Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review 1.305
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents 980
Current insights in obstetric antiphospholipid syndrome 608
The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction 487
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence 480
Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review 461
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome 452
Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review 442
Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials 434
Pregnancy outcomes in mixed connective tissue disease: a multicentre study 369
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study 356
Clinical utility of the global anti-phospholipid syndrome score for risk stratification: A pooled analysis 354
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab 320
The risk of ischaemic stroke in primary APS patients: a prospective study 291
Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? 267
Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome 236
Treatment of antiphospholipid syndrome 219
Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome 203
Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management 203
Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS 192
Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring 179
Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: A multicentre cohort study 165
Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score 157
The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study 156
Antiphospholipid antibodies: crossroads between autoimmunity and infections? 155
Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay 152
Reliability of lupus anticoagulant and anti-phosphatidylserine/prothrombin autoantibodies in antiphospholipid syndrome: A multicenter study 141
Infodemiology of systemic lupus erythematous using Google Trends 132
Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris 129
Thrombotic antiphospholipid syndrome 126
Filling the gap in antiphospholipid syndrome diagnosis: a patient's story 117
Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis 116
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome 113
Prevalence and Thrombotic Risk Assessment of Anti-beta(2) Glycoprotein I Domain I Antibodies: A Systematic Review 112
Antiphospholipid antibodies negativization: Time for testing for non-criteria aPL? 111
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort 105
Recent advances in the management of systemic lupus erythematosus 102
Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 99
Tailoring tofacitinib oral therapy in rheumatoid arthritis: The TuTORApp—a usability study 89
Hydroxychloroquine reduces IL-6 and pro-thrombotic status 89
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 85
Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss 83
Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis 82
Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort 78
Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion 77
Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review 77
Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients 76
Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study 75
Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease 74
IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients 73
Antiphospholipid Syndrome Is Still a Rare Disease—Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al 73
Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology 72
Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS) 70
Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"? 68
Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus 67
The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience 65
Genetic factors in antiphospholipid syndrome: Preliminary experience with whole exome sequencing 61
The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities 59
Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome 55
Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation 55
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies 54
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets 53
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 52
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome 52
Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients 50
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study 48
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 44
Pregnancy outcomes in Behçet's disease: Results from a monocentric cohort 42
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach 42
Antiphospholipid Antibodies and Infection: Non Nova Sed Nove 41
Endothelial dysfunction and cardiovascular risk in lupus nephritis: new roles for old players? 40
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies 34
Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients 33
"How we treat" clinical dilemmas in antiphospholipid syndrome: A case-based approach 31
Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine/ prothrombin antibodies 30
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 28
Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review 27
Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome 26
Detection of Autoantibodies in Saliva as New Avenue for the Diagnosis and Management of Autoimmune Patients 24
The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes 24
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol 23
Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head 23
What can Google and Wikipedia can tell us about a disease? Big Data trends analysis in Systemic Lupus Erythematosus 23
Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease 23
Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies 22
Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. 22
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 22
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience 20
Health inequalities and social determinants of health: The role of syndemics in rheumatic diseases 19
Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians 19
Renal Fibrosis in Lupus Nephritis 17
Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet’s Disease: A Systematic Review 16
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App 15
Serum Biomarkers of Renal Fibrosis: A Systematic Review 14
Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study 14
Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study) 13
Reply to comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 11
New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing 9
Renal involvement as a unique manifestation of hemophagocytic syndrome 4
2023 ACR/EULAR classification criteria in existing research cohorts: an international study 4
Totale 13.737
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019432 0 0 0 0 0 0 0 0 0 0 238 194
2019/20202.502 147 128 129 265 180 207 249 250 315 241 207 184
2020/20212.793 172 216 291 295 275 206 205 185 226 236 211 275
2021/20222.500 198 208 177 216 271 209 225 178 168 119 238 293
2022/20232.459 211 195 152 177 194 484 176 202 224 110 188 146
2023/20241.877 240 236 170 174 228 212 149 197 70 176 25 0
Totale 13.762